Business

Winnipeg Free Press - ONLINE EDITION

Cangene to acquire hemophilia compound in multimillion-dollar deal

By: Staff Writer

Posted: 02/6/2013 12:14 PM | Comments: 0 | Last Modified: 02/6/2013 12:28 PM | Updates

Winnipeg-based Cangene Corp. is to acquire an investigational hemophilia compound called IB1001 from the French company Ipsen and Inspiration Biopharmaceuticals, Inc., a Cambridge, Mass. company that is in bankruptcy protection.

Under the terms of the agreement, Cangene will pay approximately $5.9 million up front for IB1001 and other acquired assets, as well as tiered royalties on net sales and additional payments if certain sales milestones are achieved.

A press release issued by Paris-based Ipsen said in addition to the upfront fee Cangene has agreed to up to $50 million in potential additional commercial milestones.

IB1001 is being developed for the treatment and prevention of bleeding episodes in people with hemophilia B. There are two phase III clinical trials on-going.

John A. Sedor, president and CEO of Cangene, says, "The acquisition of IB1001 is consistent with our strategy of targeting late stage products to drive growth in our commercial business."

History

Updated on Wednesday, February 6, 2013 at 12:28 PM CST: corrects typo in headline

Fact Check

Have you found an error, or know of something we’ve missed in one of our stories? Please use the form below and let us know.

* Required

In which story did you find the error? *
Please post the headline of the story or the title of the video with the error.
What was the error? *
Please post exactly what was wrong with the story.
What should we have written?
Please indicate your source for the correct information.
Who else should we interview to improve this story?
Please include any contact information you may have.
Can we contact you in the future for advice on stories about this topic?
Yes

No
First Name: *
Last Name: *
E–mail Address: *
This will only be used to contact you if we have a question about your submission, it will not be used to identify you or be published.
Phone: *
This will only be used to contact you if we have a question about your submission, it will not be used to identify you or be published.
Colour:
Are you blue? If you can see this, leave it blank and get some CSS support.
Enter the words that you see: * This is to prevent our forms from being filled out automatically.
You have failed to correctly identify the words in the box above. Please try again.

More Business

Undock

You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is register and/or login and you can join the conversation and give your feedback.

Have Your Say

New to commenting? Check out our Frequently Asked Questions.

The Winnipeg Free Press does not necessarily endorse any of the views posted. By submitting your comment, you agree to our Terms and Conditions. These terms were revised effective April 16, 2010.